organization · Reporting owner
Longitude Venture Partners III, L.P.
Disclosed activity across 6 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Axonics, Inc.AXNX · Entity 86004 | 10% owner | November 02, 2018 | November 02, 2018 |
| Inozyme Pharma, Inc.INZY · Entity 77717 | 10% owner | April 19, 2022 | April 21, 2022 |
| Molecular Templates, Inc.MTEM · Entity 85987 | 10% owner | August 28, 2020 | September 01, 2020 |
| Tourmaline Bio, Inc.TALS · Entity 15643 | 10% owner | May 11, 2021 | May 11, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Axonics, Inc.
Report date November 02, 2018 · Filed November 02, 2018
Jointly reported with Longitude Capital Partners III, LLC, ENRIGHT PATRICK G
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Longitude Venture Partners III, L.P. | 2,933,333 |
Last balance in matching sequence
After 2018-11-02 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2018-11-02 · Conversion · Acquired 2,400,000 · Balance 2,400,000 F1: Reflects a 1.2-for-1 forward stock split of the Issuer's common stock effected on October 18, 2018. F2: Effective upon the closing of the Issuer's initial public offering of its common stock under the Securities Act of 1933, as amended, each share of Series C preferred stock automatically converted into 1.2 shares of the Issuer's common stock. The Series C preferred stock had no expiration date. F3: These shares are held directly by Longitude Venture Partners III, L.P. ("Longitude Venture III"). Longitude Capital Partners III, LLC ("Longitude Capital III") is the general partner of Longitude Venture III and may be deemed to have voting, investment and dispositive power with respect to these securities. Patrick G. Enright and Juliet Tammenoms Bakker, a member of the Issuer's board of directors, are the managing members of Longitude Capital III (each a "Manager" and collectively, the "Managers") and may each be deemed to share voting, investment and dispositive power with respect to these securities. Each of Longitude Capital III and the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Row 2 · 2018-11-02 · Purchase · Acquired 533,333 · Balance 2,933,333 F1: Reflects a 1.2-for-1 forward stock split of the Issuer's common stock effected on October 18, 2018. F3: These shares are held directly by Longitude Venture Partners III, L.P. ("Longitude Venture III"). Longitude Capital Partners III, LLC ("Longitude Capital III") is the general partner of Longitude Venture III and may be deemed to have voting, investment and dispositive power with respect to these securities. Patrick G. Enright and Juliet Tammenoms Bakker, a member of the Issuer's board of directors, are the managing members of Longitude Capital III (each a "Manager" and collectively, the "Managers") and may each be deemed to share voting, investment and dispositive power with respect to these securities. Each of Longitude Capital III and the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectBy Longitude Venture Partners III, L.P. | 0 |
Reported balance
After 2018-11-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-11-02 · Conversion · Disposed 2,000,000 · Balance 0 F2: Effective upon the closing of the Issuer's initial public offering of its common stock under the Securities Act of 1933, as amended, each share of Series C preferred stock automatically converted into 1.2 shares of the Issuer's common stock. The Series C preferred stock had no expiration date. F1: Reflects a 1.2-for-1 forward stock split of the Issuer's common stock effected on October 18, 2018. F3: These shares are held directly by Longitude Venture Partners III, L.P. ("Longitude Venture III"). Longitude Capital Partners III, LLC ("Longitude Capital III") is the general partner of Longitude Venture III and may be deemed to have voting, investment and dispositive power with respect to these securities. Patrick G. Enright and Juliet Tammenoms Bakker, a member of the Issuer's board of directors, are the managing members of Longitude Capital III (each a "Manager" and collectively, the "Managers") and may each be deemed to share voting, investment and dispositive power with respect to these securities. Each of Longitude Capital III and the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects a 1.2-for-1 forward stock split of the Issuer's common stock effected on October 18, 2018.
F2: Effective upon the closing of the Issuer's initial public offering of its common stock under the Securities Act of 1933, as amended, each share of Series C preferred stock automatically converted into 1.2 shares of the Issuer's common stock. The Series C preferred stock had no expiration date.
F3: These shares are held directly by Longitude Venture Partners III, L.P. ("Longitude Venture III"). Longitude Capital Partners III, LLC ("Longitude Capital III") is the general partner of Longitude Venture III and may be deemed to have voting, investment and dispositive power with respect to these securities. Patrick G. Enright and Juliet Tammenoms Bakker, a member of the Issuer's board of directors, are the managing members of Longitude Capital III (each a "Manager" and collectively, the "Managers") and may each be deemed to share voting, investment and dispositive power with respect to these securities. Each of Longitude Capital III and the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Inozyme Pharma, Inc.
Report date April 19, 2022 · Filed April 21, 2022
Jointly reported with Longitude Capital Partners III, LLC, Tammenoms Bakker Juliet, ENRIGHT PATRICK G
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Longitude Venture Partners III, L.P. | 4,174,379 |
Reported balance
After 2022-04-19 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2022-04-19 · Purchase · Acquired 1,355,000 · Balance 4,174,379 F1: These shares are held by Longitude Venture Partners III, L.P. ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and dispositive power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and dispositive power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are held by Longitude Venture Partners III, L.P. ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and dispositive power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and dispositive power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Molecular Templates, Inc.
Report date August 28, 2020 · Filed September 01, 2020
Jointly reported with Longitude Capital Partners III, LLC, ENRIGHT PATRICK G, Tammenoms Bakker Juliet
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2020-08-28 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2020-08-28 · Sale · Disposed 2,447 · Balance 0 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.63 to $10.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2: These shares were held directly by Juliet Tammenoms Bakker ("Ms. Bakker"). |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2020-08-28 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2020-08-28 · Sale · Disposed 1,049 · Balance 0 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.63 to $10.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F3: These shares were held by a trust. Ms. Bakker is the Investment Trustee of such trust and may be deemed to share voting and dispositive power with regard to the reported shares. Ms. Bakker disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. Each of the Reporting Persons disclaims the existence of a "group" and, other than Ms. Bakker, disclaims beneficial ownership of these securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 3,495 |
Reported balance
Holding disclosure · report date 2020-08-28 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 3,495 F5: These shares are held by a limited partnership (the "Partnership") of which the general partner is a trust (the "Trust"). Mr. Enright is the Trustee of the Trust and may be deemed to share voting, investment and dispositive power over the shares held by the Partnership. Each of the Trust and Mr. Enright disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Each of the Reporting Persons disclaims the existence of a "group" and, other than Mr. Enright, disclaims beneficial ownership of these securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy Longitude Venture Partners III, L.P. | 3,199,035 |
Reported balance
Holding disclosure · report date 2020-08-28 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 3,199,035 F4: These shares are held by Longitude Venture Partners III, L.P. ("Longitude Venture III"). This report is filed jointly by Longitude Capital Partners III, LLC ("Longitude Capital III"), Longitude Venture III, Patrick G. Enright ("Mr. Enright"), and Ms. Bakker. Longitude Capital III is the general partner of Longitude Venture III and may be deemed to have voting, investment and dispositive power over the shares held by Longitude Venture III. Mr. Enright and Ms. Bakker are the managing members of Longitude Capital III and may be deemed to share voting, investment and dispositive power over the shares held by Longitude Venture III. Each of Longitude Capital III, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.63 to $10.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
F2: These shares were held directly by Juliet Tammenoms Bakker ("Ms. Bakker").
F3: These shares were held by a trust. Ms. Bakker is the Investment Trustee of such trust and may be deemed to share voting and dispositive power with regard to the reported shares. Ms. Bakker disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. Each of the Reporting Persons disclaims the existence of a "group" and, other than Ms. Bakker, disclaims beneficial ownership of these securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
F4: These shares are held by Longitude Venture Partners III, L.P. ("Longitude Venture III"). This report is filed jointly by Longitude Capital Partners III, LLC ("Longitude Capital III"), Longitude Venture III, Patrick G. Enright ("Mr. Enright"), and Ms. Bakker. Longitude Capital III is the general partner of Longitude Venture III and may be deemed to have voting, investment and dispositive power over the shares held by Longitude Venture III. Mr. Enright and Ms. Bakker are the managing members of Longitude Capital III and may be deemed to share voting, investment and dispositive power over the shares held by Longitude Venture III. Each of Longitude Capital III, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein.
F5: These shares are held by a limited partnership (the "Partnership") of which the general partner is a trust (the "Trust"). Mr. Enright is the Trustee of the Trust and may be deemed to share voting, investment and dispositive power over the shares held by the Partnership. Each of the Trust and Mr. Enright disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Each of the Reporting Persons disclaims the existence of a "group" and, other than Mr. Enright, disclaims beneficial ownership of these securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
Tourmaline Bio, Inc.
Report date May 11, 2021 · Filed May 11, 2021
Jointly reported with Longitude Capital Partners III, LLC, ENRIGHT PATRICK G, Tammenoms Bakker Juliet
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Longitude Venture Partners III, L.P. | 3,220,775 |
Last balance in matching sequence
After 2021-05-11 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2021-05-11 · Conversion · Acquired 2,985,775 · Balance 2,985,775 F1: Each share of Series A Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series A-1 Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series B Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock had no expiration date. F2: These shares are held by Longitude Venture Partners III, L.P ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and investment power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and investment power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Row 2 · 2021-05-11 · Purchase · Acquired 235,000 · Balance 3,220,775 F3: On May 11, 2021, LVP III purchased 235,000 shares of Common Stock of the Issuer at a price of $17.00 per share pursuant to an underwritten public offering. F2: These shares are held by Longitude Venture Partners III, L.P ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and investment power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and investment power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectBy Longitude Venture Partners III, L.P. | 0 |
Reported balance
After 2021-05-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-05-11 · Conversion · Disposed 1,308,410 · Balance 0 F1: Each share of Series A Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series A-1 Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series B Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock had no expiration date. F2: These shares are held by Longitude Venture Partners III, L.P ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and investment power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and investment power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
| Series A-1 Preferred StockSEC Table II · derivative / convertible security | IndirectBy Longitude Venture Partners III, L.P. | 0 |
Reported balance
After 2021-05-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-05-11 · Conversion · Disposed 1,271,027 · Balance 0 F1: Each share of Series A Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series A-1 Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series B Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock had no expiration date. F2: These shares are held by Longitude Venture Partners III, L.P ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and investment power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and investment power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy Longitude Venture Partners III, L.P. | 0 |
Reported balance
After 2021-05-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-05-11 · Conversion · Disposed 406,338 · Balance 0 F1: Each share of Series A Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series A-1 Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series B Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock had no expiration date. F2: These shares are held by Longitude Venture Partners III, L.P ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and investment power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and investment power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series A Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series A-1 Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series B Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock had no expiration date.
F2: These shares are held by Longitude Venture Partners III, L.P ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and investment power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and investment power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
F3: On May 11, 2021, LVP III purchased 235,000 shares of Common Stock of the Issuer at a price of $17.00 per share pursuant to an underwritten public offering.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
89bio, Inc.
Report date November 16, 2020 · Filed November 18, 2020
Jointly reported with Longitude Capital Partners III, LLC, Tammenoms Bakker Juliet, ENRIGHT PATRICK G
Section 16 reporting ended · disclosed 2020-11-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,750,877 |
Reported balance
After 2020-11-16 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2020-11-16 · Other · Disposed 850,000 · Balance 1,750,877 F1: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Venture Partners III, L.P. ("Longitude Venture III") to its general and limited partners. F2: These shares are held directly by Longitude Venture III. Longitude Capital Partners III, LLC ("Longitude Capital III") is the general partner of Longitude Venture III and may be deemed to have voting, investment and dispositive power with respect to these securities. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of Longitude Capital III (each a "Manager" and collectively, the "Managers") and may each be deemed to share voting, investment and dispositive power with respect to these securities. Each of Longitude Capital III and the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,973 |
Reported balance
After 2020-11-16 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2020-11-16 · Other · Acquired 2,973 · Balance 2,973 F3: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Capital III to its members. F4: These shares are held by a limited partnership (the "Partnership") of which the general partner is a trust (the "Trust"). Mr. Enright is the Trustee of the Trust and may be deemed to share voting, investment and dispositive power over the shares held by the Partnership. Each of the Trust and Mr. Enright disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Each of the Reporting Persons disclaims the existence of a "group" and, other than Mr. Enright, disclaims beneficial ownership of these securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,080 |
Reported balance
After 2020-11-16 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2020-11-16 · Other · Acquired 2,080 · Balance 2,080 F3: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Capital III to its members. F5: These shares are held by a trust. Ms. Bakker is the Investment Trustee of such trust and may be deemed to share voting and dispositive power with regard to the reported shares. Ms. Bakker disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. Each of the Reporting Persons disclaims the existence of a "group" and, other than Ms. Bakker, disclaims beneficial ownership of these securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 891 |
Reported balance
After 2020-11-16 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2020-11-16 · Other · Acquired 891 · Balance 891 F3: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Capital III to its members. F6: These shares are held directly by Ms. Bakker. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Venture Partners III, L.P. ("Longitude Venture III") to its general and limited partners.
F2: These shares are held directly by Longitude Venture III. Longitude Capital Partners III, LLC ("Longitude Capital III") is the general partner of Longitude Venture III and may be deemed to have voting, investment and dispositive power with respect to these securities. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of Longitude Capital III (each a "Manager" and collectively, the "Managers") and may each be deemed to share voting, investment and dispositive power with respect to these securities. Each of Longitude Capital III and the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
F3: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Capital III to its members.
F4: These shares are held by a limited partnership (the "Partnership") of which the general partner is a trust (the "Trust"). Mr. Enright is the Trustee of the Trust and may be deemed to share voting, investment and dispositive power over the shares held by the Partnership. Each of the Trust and Mr. Enright disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Each of the Reporting Persons disclaims the existence of a "group" and, other than Mr. Enright, disclaims beneficial ownership of these securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
F5: These shares are held by a trust. Ms. Bakker is the Investment Trustee of such trust and may be deemed to share voting and dispositive power with regard to the reported shares. Ms. Bakker disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. Each of the Reporting Persons disclaims the existence of a "group" and, other than Ms. Bakker, disclaims beneficial ownership of these securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
F6: These shares are held directly by Ms. Bakker.
Sierra Oncology, Inc.
Report date April 27, 2022 · Filed April 29, 2022
Jointly reported with Longitude Capital Partners III, LLC, Tammenoms Bakker Juliet, ENRIGHT PATRICK G, Longitude Prime Partners, LLC, Longitude Prime Fund, L.P.
Section 16 reporting ended · disclosed 2022-04-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2022-04-27 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2022-04-27 · Other · Disposed 175,000 · Balance 0 F1: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Prime Fund, L.P. ("LPF") to its general and limited partners. F2: The securities are held directly by LPF. Longitude Prime Partners, LLC ("LPP"), the general partner of LPF, may be deemed to have voting and investment power with respect to the shares held by LPF. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LPP and may be deemed to share voting, investment and dispositive power over such securities. Each of LPP, Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2022-04-27 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2022-04-27 · Other · Disposed 1,964,771 · Balance 0 F3: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Venture Partners III, L.P. ("LVP III") to its general and limited partners. F4: These securities are held directly by LVP III. Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting, investment and dispositive power with respect to such securities. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP III and may be deemed to share voting, investment and dispositive power over such securities. Each of LCP III, Mr. Enright, and Ms. Tammenoms Bakker disclaim beneficial ownership over such securities except to the extent of their respective pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 5,023 |
Reported balance
After 2022-04-27 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2022-04-27 · Other · Acquired 5,023 · Balance 5,023 F5: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LCP III to its members. F6: These shares are held directly by Juliet Tammenoms Bakker. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,152 |
Reported balance
After 2022-04-27 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2022-04-27 · Other · Acquired 2,152 · Balance 2,152 F5: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LCP III to its members. F7: These shares are held by a trust. Juliet Tammenoms Bakker is the Investment Trustee of such trust and may be deemed to share voting and dispositive power with regard to the reported shares. Ms. Tammenoms Bakker disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 7,175 |
Reported balance
After 2022-04-27 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2022-04-27 · Other · Acquired 7,175 · Balance 7,175 F5: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LCP III to its members. F8: These shares are held directly by Patrick G. Enright. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 5,611 |
Reported balance
After 2022-04-27 transaction · row 6
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 6 · 2022-04-27 · Other · Acquired 588 · Balance 5,611 F9: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LPP to its members F6: These shares are held directly by Juliet Tammenoms Bakker. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,404 |
Reported balance
After 2022-04-27 transaction · row 7
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 7 · 2022-04-27 · Other · Acquired 252 · Balance 2,404 F9: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LPP to its members F7: These shares are held by a trust. Juliet Tammenoms Bakker is the Investment Trustee of such trust and may be deemed to share voting and dispositive power with regard to the reported shares. Ms. Tammenoms Bakker disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 8,015 |
Reported balance
After 2022-04-27 transaction · row 8
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 8 · 2022-04-27 · Other · Acquired 840 · Balance 8,015 F9: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LPP to its members F8: These shares are held directly by Patrick G. Enright. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Prime Fund, L.P. ("LPF") to its general and limited partners.
F2: The securities are held directly by LPF. Longitude Prime Partners, LLC ("LPP"), the general partner of LPF, may be deemed to have voting and investment power with respect to the shares held by LPF. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LPP and may be deemed to share voting, investment and dispositive power over such securities. Each of LPP, Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
F3: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Venture Partners III, L.P. ("LVP III") to its general and limited partners.
F4: These securities are held directly by LVP III. Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting, investment and dispositive power with respect to such securities. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP III and may be deemed to share voting, investment and dispositive power over such securities. Each of LCP III, Mr. Enright, and Ms. Tammenoms Bakker disclaim beneficial ownership over such securities except to the extent of their respective pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
F5: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LCP III to its members.
F6: These shares are held directly by Juliet Tammenoms Bakker.
F7: These shares are held by a trust. Juliet Tammenoms Bakker is the Investment Trustee of such trust and may be deemed to share voting and dispositive power with regard to the reported shares. Ms. Tammenoms Bakker disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein.
F8: These shares are held directly by Patrick G. Enright.
F9: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LPP to its members
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 27, 2022 Filed Apr 29, 2022 19:07 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | OtherCommon Stock | 840 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-016052 · doc4.xml · nonDerivative · entry 8 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner Longitude Prime Fund, L.P. · CIK 0001865844 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 8,015 F9 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LPP to its members F8 · ownership.nature: These shares are held directly by Patrick G. Enright. Read SEC document |
| April 27, 2022 Filed Apr 29, 2022 19:07 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | OtherCommon Stock | 252 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-016052 · doc4.xml · nonDerivative · entry 7 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner Longitude Prime Fund, L.P. · CIK 0001865844 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,404 F9 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LPP to its members F7 · ownership.nature: These shares are held by a trust. Juliet Tammenoms Bakker is the Investment Trustee of such trust and may be deemed to share voting and dispositive power with regard to the reported shares. Ms. Tammenoms Bakker disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. Read SEC document |
| April 27, 2022 Filed Apr 29, 2022 19:07 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | OtherCommon Stock | 588 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-016052 · doc4.xml · nonDerivative · entry 6 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner Longitude Prime Fund, L.P. · CIK 0001865844 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,611 F9 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LPP to its members F6 · ownership.nature: These shares are held directly by Juliet Tammenoms Bakker. Read SEC document |
| April 27, 2022 Filed Apr 29, 2022 19:07 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | OtherCommon Stock | 7,175 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-016052 · doc4.xml · nonDerivative · entry 5 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner Longitude Prime Fund, L.P. · CIK 0001865844 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 7,175 F5 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LCP III to its members. F8 · ownership.nature: These shares are held directly by Patrick G. Enright. Read SEC document |
| April 27, 2022 Filed Apr 29, 2022 19:07 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | OtherCommon Stock | 2,152 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-016052 · doc4.xml · nonDerivative · entry 4 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner Longitude Prime Fund, L.P. · CIK 0001865844 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,152 F5 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LCP III to its members. F7 · ownership.nature: These shares are held by a trust. Juliet Tammenoms Bakker is the Investment Trustee of such trust and may be deemed to share voting and dispositive power with regard to the reported shares. Ms. Tammenoms Bakker disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. Read SEC document |
| April 27, 2022 Filed Apr 29, 2022 19:07 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | OtherCommon Stock | 5,023 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-016052 · doc4.xml · nonDerivative · entry 3 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner Longitude Prime Fund, L.P. · CIK 0001865844 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,023 F5 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LCP III to its members. F6 · ownership.nature: These shares are held directly by Juliet Tammenoms Bakker. Read SEC document |
| April 27, 2022 Filed Apr 29, 2022 19:07 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | OtherCommon Stock | 1,964,771 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-016052 · doc4.xml · nonDerivative · entry 2 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner Longitude Prime Fund, L.P. · CIK 0001865844 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F3 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Venture Partners III, L.P. ("LVP III") to its general and limited partners. F4 · ownership.nature: These securities are held directly by LVP III. Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting, investment and dispositive power with respect to such securities. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP III and may be deemed to share voting, investment and dispositive power over such securities. Each of LCP III, Mr. Enright, and Ms. Tammenoms Bakker disclaim beneficial ownership over such securities except to the extent of their respective pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| April 27, 2022 Filed Apr 29, 2022 19:07 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | OtherCommon Stock | 175,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-016052 · doc4.xml · nonDerivative · entry 1 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner Longitude Prime Fund, L.P. · CIK 0001865844 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Prime Fund, L.P. ("LPF") to its general and limited partners. F2 · ownership.nature: The securities are held directly by LPF. Longitude Prime Partners, LLC ("LPP"), the general partner of LPF, may be deemed to have voting and investment power with respect to the shares held by LPF. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LPP and may be deemed to share voting, investment and dispositive power over such securities. Each of LPP, Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| April 19, 2022 Filed Apr 21, 2022 18:04 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | PurchaseCommon Stock | 1,355,000 | $3.69 | $4,999,950.00 |
DisclosureSEC source: 0000899243-22-015325 · doc4.xml · nonDerivative · entry 1 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Longitude Venture Partners III, L.P. Disclosed balance after: 4,174,379 F1 · ownership.nature: These shares are held by Longitude Venture Partners III, L.P. ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and dispositive power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and dispositive power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| February 02, 2022 Filed Feb 2, 2022 21:25 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | PurchaseCommon Stock | 175,000 | $27.00 | $4,725,000.00 |
DisclosureSEC source: 0000899243-22-004271 · doc4.xml · nonDerivative · entry 1 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner Longitude Prime Fund, L.P. · CIK 0001865844 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 175,000 F1 · ownership.nature: The securities are held directly by Longitude Prime Fund, L.P. ("LPF"). Longitude Prime Partners, LLC ("LPP"), the general partner of LPF, may be deemed to have voting and investment power with respect to the shares held by LPF. Patrick G. Enright, Juliet Tammenoms Bakker and Joshua Richardson, a member of the Issuer's board of directors, are each members of LPF and may be deemed to share voting, investment and dispositive power over such securities. Mr. Enright and Ms. Tammenoms Bakker are the managing members of LPP. Each of Mr. Enright, Ms. Tammenoms Bakker and Dr. Richardson disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| January 25, 2022 Filed Jan 27, 2022 21:23 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | OtherSeries B Warrants · Derivative | 1,477,125 | $13.20 Strike: $13.20 | $19,498,050.00 |
DisclosureSEC source: 0000899243-22-003502 · doc4.xml · derivative · entry 2 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 487,451 shares Expires 2022-04-10 F2 · shares: Consists of 1,477,125 Series B Warrants held by LVP III which are exercisable for an aggregate of 487,451 shares of Common Stock. F1 · ownership.nature: These securities are held directly by Longitude Venture Partners III, L.P. ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting, investment and dispositive power with respect to such securities. Patrick G. Enright, Juliet Tammenoms Bakker and Joshua Richardson, a member of the Issuer's board of directors, are each members of LCP III and may be deemed to share voting, investment and dispositive power over such securities. Mr. Enright and Ms. Tammenoms Bakker are the managing members of LCP III. Each of LCP III, Mr. Enright, Ms. Tammenoms Bakker and Joshua Richardson disclaim beneficial ownership over such securities except to the extent of their respective pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| January 25, 2022 Filed Jan 27, 2022 21:23 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | OtherCommon Stock | 487,451 | $13.20 | $6,434,353.20 |
DisclosureSEC source: 0000899243-22-003502 · doc4.xml · nonDerivative · entry 1 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,964,771 F1 · ownership.nature: These securities are held directly by Longitude Venture Partners III, L.P. ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting, investment and dispositive power with respect to such securities. Patrick G. Enright, Juliet Tammenoms Bakker and Joshua Richardson, a member of the Issuer's board of directors, are each members of LCP III and may be deemed to share voting, investment and dispositive power over such securities. Mr. Enright and Ms. Tammenoms Bakker are the managing members of LCP III. Each of LCP III, Mr. Enright, Ms. Tammenoms Bakker and Joshua Richardson disclaim beneficial ownership over such securities except to the extent of their respective pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 11, 2021 Filed May 11, 2021 20:29 UTC | Tourmaline Bio, Inc. TALS · Entity 15643 | ConversionSeries B Preferred Stock · Derivative | 406,338 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-019166 · doc4.xml · derivative · entry 5 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Longitude Venture Partners III, L.P. Disclosed balance after: 0 Underlying: Common Stock · 406,338 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series A-1 Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series B Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series A-1 Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series B Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series A-1 Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series B Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock had no expiration date. F2 · ownership.nature: These shares are held by Longitude Venture Partners III, L.P ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and investment power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and investment power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 11, 2021 Filed May 11, 2021 20:29 UTC | Tourmaline Bio, Inc. TALS · Entity 15643 | ConversionSeries A-1 Preferred Stock · Derivative | 1,271,027 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-019166 · doc4.xml · derivative · entry 4 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Longitude Venture Partners III, L.P. Disclosed balance after: 0 Underlying: Common Stock · 1,271,027 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series A-1 Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series B Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series A-1 Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series B Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series A-1 Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series B Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock had no expiration date. F2 · ownership.nature: These shares are held by Longitude Venture Partners III, L.P ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and investment power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and investment power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 11, 2021 Filed May 11, 2021 20:29 UTC | Tourmaline Bio, Inc. TALS · Entity 15643 | ConversionSeries A Preferred Stock · Derivative | 1,308,410 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-019166 · doc4.xml · derivative · entry 3 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Longitude Venture Partners III, L.P. Disclosed balance after: 0 Underlying: Common Stock · 1,308,410 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series A-1 Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series B Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series A-1 Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series B Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series A-1 Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series B Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock had no expiration date. F2 · ownership.nature: These shares are held by Longitude Venture Partners III, L.P ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and investment power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and investment power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 11, 2021 Filed May 11, 2021 20:29 UTC | Tourmaline Bio, Inc. TALS · Entity 15643 | PurchaseCommon Stock | 235,000 | $17.00 | $3,995,000.00 |
DisclosureSEC source: 0000899243-21-019166 · doc4.xml · nonDerivative · entry 2 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Longitude Venture Partners III, L.P. Disclosed balance after: 3,220,775 F3 · price: On May 11, 2021, LVP III purchased 235,000 shares of Common Stock of the Issuer at a price of $17.00 per share pursuant to an underwritten public offering. F2 · ownership.nature: These shares are held by Longitude Venture Partners III, L.P ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and investment power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and investment power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 11, 2021 Filed May 11, 2021 20:29 UTC | Tourmaline Bio, Inc. TALS · Entity 15643 | ConversionCommon Stock | 2,985,775 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-019166 · doc4.xml · nonDerivative · entry 1 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Longitude Venture Partners III, L.P. Disclosed balance after: 2,985,775 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series A-1 Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series B Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock had no expiration date. F2 · ownership.nature: These shares are held by Longitude Venture Partners III, L.P ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and investment power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and investment power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 19:11 UTC | 89bio, Inc. ETNB · Entity 73682 | OtherCommon Stock | 891 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-031489 · doc4.xml · nonDerivative · entry 4 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 891 F3 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Capital III to its members. F6 · ownership.nature: These shares are held directly by Ms. Bakker. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 19:11 UTC | 89bio, Inc. ETNB · Entity 73682 | OtherCommon Stock | 2,080 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-031489 · doc4.xml · nonDerivative · entry 3 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,080 F3 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Capital III to its members. F5 · ownership.nature: These shares are held by a trust. Ms. Bakker is the Investment Trustee of such trust and may be deemed to share voting and dispositive power with regard to the reported shares. Ms. Bakker disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. Each of the Reporting Persons disclaims the existence of a "group" and, other than Ms. Bakker, disclaims beneficial ownership of these securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 19:11 UTC | 89bio, Inc. ETNB · Entity 73682 | OtherCommon Stock | 2,973 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-031489 · doc4.xml · nonDerivative · entry 2 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,973 F3 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Capital III to its members. F4 · ownership.nature: These shares are held by a limited partnership (the "Partnership") of which the general partner is a trust (the "Trust"). Mr. Enright is the Trustee of the Trust and may be deemed to share voting, investment and dispositive power over the shares held by the Partnership. Each of the Trust and Mr. Enright disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Each of the Reporting Persons disclaims the existence of a "group" and, other than Mr. Enright, disclaims beneficial ownership of these securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 19:11 UTC | 89bio, Inc. ETNB · Entity 73682 | OtherCommon Stock | 850,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-031489 · doc4.xml · nonDerivative · entry 1 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,750,877 F1 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Venture Partners III, L.P. ("Longitude Venture III") to its general and limited partners. F2 · ownership.nature: These shares are held directly by Longitude Venture III. Longitude Capital Partners III, LLC ("Longitude Capital III") is the general partner of Longitude Venture III and may be deemed to have voting, investment and dispositive power with respect to these securities. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of Longitude Capital III (each a "Manager" and collectively, the "Managers") and may each be deemed to share voting, investment and dispositive power with respect to these securities. Each of Longitude Capital III and the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| August 28, 2020 Filed Sep 1, 2020 19:33 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | SaleCommon Stock | 1,049 | $10.75 | $11,272.66 |
DisclosureSEC source: 0000899243-20-023790 · doc4.xml · nonDerivative · entry 2 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.63 to $10.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F3 · ownership.nature: These shares were held by a trust. Ms. Bakker is the Investment Trustee of such trust and may be deemed to share voting and dispositive power with regard to the reported shares. Ms. Bakker disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. Each of the Reporting Persons disclaims the existence of a "group" and, other than Ms. Bakker, disclaims beneficial ownership of these securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| August 28, 2020 Filed Sep 1, 2020 19:33 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | SaleCommon Stock | 2,447 | $10.75 | $26,295.71 |
DisclosureSEC source: 0000899243-20-023790 · doc4.xml · nonDerivative · entry 1 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.63 to $10.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · ownership.nature: These shares were held directly by Juliet Tammenoms Bakker ("Ms. Bakker"). Read SEC document |
| July 28, 2020 Filed Jul 28, 2020 18:20 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | ConversionSeries A-2 Convertible Preferred Stock · Derivative | 1,398,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-020572 · doc4.xml · derivative · entry 5 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Longitude Venture Partners III, L.P. Disclosed balance after: 0 Underlying: Common Stock · 187,154 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: On July 28, 2020, the Series A-2 Convertible Preferred Stock automatically converted into Common Stock on a 7.4730-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F3 · derivative.exercise_date: On July 28, 2020, the Series A-2 Convertible Preferred Stock automatically converted into Common Stock on a 7.4730-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F3 · derivative.expiration_date: On July 28, 2020, the Series A-2 Convertible Preferred Stock automatically converted into Common Stock on a 7.4730-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2 · ownership.nature: These shares are held by Longitude Venture Partners III, L.P ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and dispositive power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and dispositive power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| July 28, 2020 Filed Jul 28, 2020 18:20 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | ConversionSeries A Convertible Preferred Stock · Derivative | 15,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-020572 · doc4.xml · derivative · entry 4 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Longitude Venture Partners III, L.P. Disclosed balance after: 0 Underlying: Common Stock · 2,007,225 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On July 28, 2020, the Series A Convertible Preferred Stock automatically converted into Common Stock on a 7.4730-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.exercise_date: On July 28, 2020, the Series A Convertible Preferred Stock automatically converted into Common Stock on a 7.4730-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.expiration_date: On July 28, 2020, the Series A Convertible Preferred Stock automatically converted into Common Stock on a 7.4730-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2 · ownership.nature: These shares are held by Longitude Venture Partners III, L.P ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and dispositive power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and dispositive power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| July 28, 2020 Filed Jul 28, 2020 18:20 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | PurchaseCommon Stock | 625,000 | $16.00 | $10,000,000.00 |
DisclosureSEC source: 0000899243-20-020572 · doc4.xml · nonDerivative · entry 3 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Longitude Venture Partners III, L.P. Disclosed balance after: 2,819,379 F2 · ownership.nature: These shares are held by Longitude Venture Partners III, L.P ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and dispositive power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and dispositive power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| July 28, 2020 Filed Jul 28, 2020 18:20 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | ConversionCommon Stock | 187,154 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-020572 · doc4.xml · nonDerivative · entry 2 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Longitude Venture Partners III, L.P. Disclosed balance after: 2,194,379 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: On July 28, 2020, the Series A-2 Convertible Preferred Stock automatically converted into Common Stock on a 7.4730-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2 · ownership.nature: These shares are held by Longitude Venture Partners III, L.P ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and dispositive power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and dispositive power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| July 28, 2020 Filed Jul 28, 2020 18:20 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | ConversionCommon Stock | 2,007,225 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-020572 · doc4.xml · nonDerivative · entry 1 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Longitude Venture Partners III, L.P. Disclosed balance after: 2,007,225 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On July 28, 2020, the Series A Convertible Preferred Stock automatically converted into Common Stock on a 7.4730-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2 · ownership.nature: These shares are held by Longitude Venture Partners III, L.P ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and dispositive power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and dispositive power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| July 10, 2020 Filed Jul 14, 2020 20:11 UTC | 89bio, Inc. ETNB · Entity 73682 | PurchaseCommon Stock | 109,090 | $27.50 | $2,999,975.00 |
DisclosureSEC source: 0000899243-20-019123 · doc4.xml · nonDerivative · entry 1 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,600,877 F1 · shares: On July 10, 2020, Longitude Venture Partners III, L.P. ("Longitude Venture III") purchased 109,090 shares of the Issuer's common stock at a price of $27.50 per share in the Issuer's follow-on public offering. F2 · ownership.nature: These shares are held directly by Longitude Venture III. Longitude Capital Partners III, LLC ("Longitude Capital III") is the general partner of Longitude Venture III and may be deemed to have voting, investment and dispositive power with respect to these securities. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of Longitude Capital III (each a "Manager" and collectively, the "Managers") and may each be deemed to share voting, investment and dispositive power with respect to these securities. Each of Longitude Capital III and the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 26, 2020 Filed May 28, 2020 21:07 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | OtherCommon Stock | 1,049 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-014482 · doc4.xml · nonDerivative · entry 4 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,049 F3 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Capital III to its members. F6 · ownership.nature: These shares are held by a trust. Ms. Bakker is the Investment Trustee of such trust and may be deemed to share voting and dispositive power with regard to the reported shares. Ms. Bakker disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. Each of the Reporting Persons disclaims the existence of a "group" and, other than Ms. Bakker, disclaims beneficial ownership of these securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 26, 2020 Filed May 28, 2020 21:07 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | OtherCommon Stock | 2,447 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-014482 · doc4.xml · nonDerivative · entry 3 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,447 F3 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Capital III to its members. F5 · ownership.nature: These shares are held directly by Ms. Bakker. Read SEC document |
| May 26, 2020 Filed May 28, 2020 21:07 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | OtherCommon Stock | 3,495 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-014482 · doc4.xml · nonDerivative · entry 2 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,495 F3 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Capital III to its members. F4 · ownership.nature: These shares are held by a limited partnership (the "Partnership") of which the general partner is a trust (the "Trust"). Mr. Enright is the Trustee of the Trust and may be deemed to share voting, investment and dispositive power over the shares held by the Partnership. Each of the Trust and Mr. Enright disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Each of the Reporting Persons disclaims the existence of a "group" and, other than Mr. Enright, disclaims beneficial ownership of these securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 26, 2020 Filed May 28, 2020 21:07 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | OtherCommon Stock | 1,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-014482 · doc4.xml · nonDerivative · entry 1 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Longitude Venture Partners III, L.P. Disclosed balance after: 3,199,035 F1 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Venture Partners III, L.P. ("Longitude Venture III") to its general and limited partners. F2 · ownership.nature: These shares are held by Longitude Venture III. This report is filed jointly by Longitude Capital Partners III, LLC ("Longitude Capital III"), Longitude Venture III, Patrick G. Enright ("Mr. Enright"), and Juliet Tammenoms Bakker ("Ms. Bakker"). Longitude Capital III is the general partner of Longitude Venture III and may be deemed to have voting, investment and dispositive power over the shares held by Longitude Venture III. Mr. Enright and Ms. Bakker are the managing members of Longitude Capital III and may be deemed to share voting, investment and dispositive power over the shares held by Longitude Venture III. Each of Longitude Capital III, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 17:45 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | ConversionSeries A Convertible Voting Preferred Stock · Derivative | 19,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-002476 · doc4.xml · derivative · entry 2 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,477,320 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series A Convertible Voting Preferred Stock (the "Series A Preferred Stock") converted into 75.76 shares of the Issuer's Common Stock for no additional consideration, as adjusted for the Reverse Split, automatically upon the 5th trading date following the Issuer's announcement of receiving stockholder approval for the first reverse stock split of the Issuer following November 13, 2019. The Series A Preferred Stock has no expiration date. F4 · shares: Consists of 19,500 shares of Series A Preferred Stock held by LVP III which are convertible into an aggregate of 1,477,320 shares of Common Stock, as adjusted for the Reverse Split. F2 · price: Each share of Series A Convertible Voting Preferred Stock (the "Series A Preferred Stock") converted into 75.76 shares of the Issuer's Common Stock for no additional consideration, as adjusted for the Reverse Split, automatically upon the 5th trading date following the Issuer's announcement of receiving stockholder approval for the first reverse stock split of the Issuer following November 13, 2019. The Series A Preferred Stock has no expiration date. F2 · derivative.exercise_date: Each share of Series A Convertible Voting Preferred Stock (the "Series A Preferred Stock") converted into 75.76 shares of the Issuer's Common Stock for no additional consideration, as adjusted for the Reverse Split, automatically upon the 5th trading date following the Issuer's announcement of receiving stockholder approval for the first reverse stock split of the Issuer following November 13, 2019. The Series A Preferred Stock has no expiration date. F2 · derivative.expiration_date: Each share of Series A Convertible Voting Preferred Stock (the "Series A Preferred Stock") converted into 75.76 shares of the Issuer's Common Stock for no additional consideration, as adjusted for the Reverse Split, automatically upon the 5th trading date following the Issuer's announcement of receiving stockholder approval for the first reverse stock split of the Issuer following November 13, 2019. The Series A Preferred Stock has no expiration date. F1 · derivative.underlying_shares: On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the "Reverse Split") was effected. These securities reflect the Reverse Split. F3 · ownership.nature: The reportable securities are owned directly by Longitude Venture Partners III, L.P. ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting, investment and dispositive power with respect to such securities. Patrick G. Enright, Juliet Tammenoms Bakker and Joshua Richardson (a member of the Issuer's board of directors), are each members of LCP III and may be deemed to share voting, investment and dispositive power over such securities. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP III. Each of LCP III, Patrick G. Enright, Juliet Tammenoms Bakker and Joshua Richardson disclaim beneficial ownership over such securities except to the extent of their respective pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 17:45 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | ConversionCommon Stock | 1,477,320 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-002476 · doc4.xml · nonDerivative · entry 1 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,477,320 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the "Reverse Split") was effected. These securities reflect the Reverse Split. F2 · price: Each share of Series A Convertible Voting Preferred Stock (the "Series A Preferred Stock") converted into 75.76 shares of the Issuer's Common Stock for no additional consideration, as adjusted for the Reverse Split, automatically upon the 5th trading date following the Issuer's announcement of receiving stockholder approval for the first reverse stock split of the Issuer following November 13, 2019. The Series A Preferred Stock has no expiration date. F1 · balance_after: On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the "Reverse Split") was effected. These securities reflect the Reverse Split. F3 · ownership.nature: The reportable securities are owned directly by Longitude Venture Partners III, L.P. ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting, investment and dispositive power with respect to such securities. Patrick G. Enright, Juliet Tammenoms Bakker and Joshua Richardson (a member of the Issuer's board of directors), are each members of LCP III and may be deemed to share voting, investment and dispositive power over such securities. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP III. Each of LCP III, Patrick G. Enright, Juliet Tammenoms Bakker and Joshua Richardson disclaim beneficial ownership over such securities except to the extent of their respective pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| November 25, 2019 Filed Nov 27, 2019 16:47 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | PurchaseCommon Stock | 937,000 | $8.00 | $7,496,000.00 |
DisclosureSEC source: 0000899243-19-028242 · doc4.xml · nonDerivative · entry 1 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Longitude Venture Partners III, L.P. Disclosed balance after: 4,198,535 F1 · shares: These shares were purchased pursuant to an underwritten public offering. F2 · ownership.direct: These shares are held by Longitude Venture Partners III, L.P. ("Longitude Venture III"). This report is filed jointly by Longitude Capital Partners III, LLC ("Longitude Capital III"), Longitude Venture III, Patrick G. Enright ("Mr. Enright"), and Juliet Tammenoms Bakker ("Ms. Bakker"), all of whom share beneficial ownership of more than 10% of the capital stock of the Issuer. Longitude Capital III is the general partner of Longitude Venture III and may be deemed to have voting, investment and dispositive power over the shares held by Longitude Venture III. Mr. Enright and Ms. Bakker are the managing members of Longitude Capital III and may be deemed to share voting, investment and dispositive power over the shares held by Longitude Venture III. Each of Longitude Capital III, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein. F2 · ownership.nature: These shares are held by Longitude Venture Partners III, L.P. ("Longitude Venture III"). This report is filed jointly by Longitude Capital Partners III, LLC ("Longitude Capital III"), Longitude Venture III, Patrick G. Enright ("Mr. Enright"), and Juliet Tammenoms Bakker ("Ms. Bakker"), all of whom share beneficial ownership of more than 10% of the capital stock of the Issuer. Longitude Capital III is the general partner of Longitude Venture III and may be deemed to have voting, investment and dispositive power over the shares held by Longitude Venture III. Mr. Enright and Ms. Bakker are the managing members of Longitude Capital III and may be deemed to share voting, investment and dispositive power over the shares held by Longitude Venture III. Each of Longitude Capital III, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein. Read SEC document |
| November 25, 2019 Filed Dec 5, 2019 16:16 UTC Amendment | Molecular Templates, Inc. MTEM · Entity 85987 | PurchaseCommon Stock | 937,500 | $8.00 | $7,500,000.00 |
DisclosureSEC source: 0000899243-19-028574 · doc4a.xml · nonDerivative · entry 1 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Longitude Venture Partners III, L.P. Disclosed balance after: 4,199,035 F1 · shares: These shares were purchased pursuant to an underwritten public offering. F2 · shares: Includes 500 shares that were inadvertently omitted from the original Form 4. F3 · ownership.direct: These shares are held by Longitude Venture Partners III, L.P. ("Longitude Venture III"). This report is filed jointly by Longitude Capital Partners III, LLC ("Longitude Capital III"), Longitude Venture III, Patrick G. Enright ("Mr. Enright"), and Juliet Tammenoms Bakker ("Ms. Bakker"), all of whom share beneficial ownership of more than 10% of the capital stock of the Issuer. Longitude Capital III is the general partner of Longitude Venture III and may be deemed to have voting, investment and dispositive power over the shares held by Longitude Venture III. Mr. Enright and Ms. Bakker are the managing members of Longitude Capital III and may be deemed to share voting, investment and dispositive power over the shares held by Longitude Venture III. Each of Longitude Capital III, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein. F3 · ownership.nature: These shares are held by Longitude Venture Partners III, L.P. ("Longitude Venture III"). This report is filed jointly by Longitude Capital Partners III, LLC ("Longitude Capital III"), Longitude Venture III, Patrick G. Enright ("Mr. Enright"), and Juliet Tammenoms Bakker ("Ms. Bakker"), all of whom share beneficial ownership of more than 10% of the capital stock of the Issuer. Longitude Capital III is the general partner of Longitude Venture III and may be deemed to have voting, investment and dispositive power over the shares held by Longitude Venture III. Mr. Enright and Ms. Bakker are the managing members of Longitude Capital III and may be deemed to share voting, investment and dispositive power over the shares held by Longitude Venture III. Each of Longitude Capital III, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein. Read SEC document |
| November 13, 2019 Filed Nov 13, 2019 19:02 UTC | 89bio, Inc. ETNB · Entity 73682 | ConversionSeries A Preferred Stock · Derivative | 11,916,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-027219 · doc4.xml · derivative · entry 3 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,916,787 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-6.217 basis immediately prior the closing of the Issuer's initial public offering on November 13, 2019 and had no expiration date. F2 · derivative.exercise_date: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-6.217 basis immediately prior the closing of the Issuer's initial public offering on November 13, 2019 and had no expiration date. F2 · derivative.expiration_date: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-6.217 basis immediately prior the closing of the Issuer's initial public offering on November 13, 2019 and had no expiration date. F3 · ownership.nature: These shares are held directly by Longitude Venture III. Longitude Capital Partners III, LLC ("Longitude Capital III") is the general partner of Longitude Venture III and may be deemed to have shared voting, investment and dispositive power with respect to these securities. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of Longitude Capital III (each a "Manager" and collectively, the "Managers") and may each be deemed to share voting, investment and dispositive power with respect to these securities. Each of Longitude Capital III and the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| November 13, 2019 Filed Nov 13, 2019 19:02 UTC | 89bio, Inc. ETNB · Entity 73682 | ConversionCommon Stock | 1,916,787 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-027219 · doc4.xml · nonDerivative · entry 2 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,491,787 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-6.217 basis immediately prior the closing of the Issuer's initial public offering on November 13, 2019 and had no expiration date. F3 · ownership.nature: These shares are held directly by Longitude Venture III. Longitude Capital Partners III, LLC ("Longitude Capital III") is the general partner of Longitude Venture III and may be deemed to have shared voting, investment and dispositive power with respect to these securities. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of Longitude Capital III (each a "Manager" and collectively, the "Managers") and may each be deemed to share voting, investment and dispositive power with respect to these securities. Each of Longitude Capital III and the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| November 11, 2019 Filed Nov 13, 2019 19:02 UTC | 89bio, Inc. ETNB · Entity 73682 | PurchaseCommon Stock | 575,000 | $16.00 | $9,200,000.00 |
DisclosureSEC source: 0000899243-19-027219 · doc4.xml · nonDerivative · entry 1 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 575,000 F1 · shares: On November 11, 2019, Longitude Venture Partners III, L.P. ("Longitude Venture III") purchased 575,000 shares of the Issuer's common stock at a price of $16.00 per share in the Issuer's initial public offering. F3 · ownership.nature: These shares are held directly by Longitude Venture III. Longitude Capital Partners III, LLC ("Longitude Capital III") is the general partner of Longitude Venture III and may be deemed to have shared voting, investment and dispositive power with respect to these securities. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of Longitude Capital III (each a "Manager" and collectively, the "Managers") and may each be deemed to share voting, investment and dispositive power with respect to these securities. Each of Longitude Capital III and the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| November 02, 2018 Filed Nov 2, 2018 19:26 UTC | Axonics, Inc. AXNX · Entity 86004 | ConversionSeries C Preferred Stock · Derivative | 2,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-028081 · doc4.xml · derivative · entry 3 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Longitude Venture Partners III, L.P. Disclosed balance after: 0 Underlying: Common Stock · 2,400,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Effective upon the closing of the Issuer's initial public offering of its common stock under the Securities Act of 1933, as amended, each share of Series C preferred stock automatically converted into 1.2 shares of the Issuer's common stock. The Series C preferred stock had no expiration date. F2 · derivative.exercise_date: Effective upon the closing of the Issuer's initial public offering of its common stock under the Securities Act of 1933, as amended, each share of Series C preferred stock automatically converted into 1.2 shares of the Issuer's common stock. The Series C preferred stock had no expiration date. F2 · derivative.expiration_date: Effective upon the closing of the Issuer's initial public offering of its common stock under the Securities Act of 1933, as amended, each share of Series C preferred stock automatically converted into 1.2 shares of the Issuer's common stock. The Series C preferred stock had no expiration date. F1 · derivative.underlying_shares: Reflects a 1.2-for-1 forward stock split of the Issuer's common stock effected on October 18, 2018. F3 · ownership.nature: These shares are held directly by Longitude Venture Partners III, L.P. ("Longitude Venture III"). Longitude Capital Partners III, LLC ("Longitude Capital III") is the general partner of Longitude Venture III and may be deemed to have voting, investment and dispositive power with respect to these securities. Patrick G. Enright and Juliet Tammenoms Bakker, a member of the Issuer's board of directors, are the managing members of Longitude Capital III (each a "Manager" and collectively, the "Managers") and may each be deemed to share voting, investment and dispositive power with respect to these securities. Each of Longitude Capital III and the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| November 02, 2018 Filed Nov 2, 2018 19:26 UTC | Axonics, Inc. AXNX · Entity 86004 | PurchaseCommon Stock | 533,333 | $15.00 | $7,999,995.00 |
DisclosureSEC source: 0000899243-18-028081 · doc4.xml · nonDerivative · entry 2 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Longitude Venture Partners III, L.P. Disclosed balance after: 2,933,333 F1 · shares: Reflects a 1.2-for-1 forward stock split of the Issuer's common stock effected on October 18, 2018. F1 · balance_after: Reflects a 1.2-for-1 forward stock split of the Issuer's common stock effected on October 18, 2018. F3 · ownership.nature: These shares are held directly by Longitude Venture Partners III, L.P. ("Longitude Venture III"). Longitude Capital Partners III, LLC ("Longitude Capital III") is the general partner of Longitude Venture III and may be deemed to have voting, investment and dispositive power with respect to these securities. Patrick G. Enright and Juliet Tammenoms Bakker, a member of the Issuer's board of directors, are the managing members of Longitude Capital III (each a "Manager" and collectively, the "Managers") and may each be deemed to share voting, investment and dispositive power with respect to these securities. Each of Longitude Capital III and the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| November 02, 2018 Filed Nov 2, 2018 19:26 UTC | Axonics, Inc. AXNX · Entity 86004 | ConversionCommon Stock | 2,400,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-028081 · doc4.xml · nonDerivative · entry 1 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Longitude Venture Partners III, L.P. Disclosed balance after: 2,400,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects a 1.2-for-1 forward stock split of the Issuer's common stock effected on October 18, 2018. F2 · price: Effective upon the closing of the Issuer's initial public offering of its common stock under the Securities Act of 1933, as amended, each share of Series C preferred stock automatically converted into 1.2 shares of the Issuer's common stock. The Series C preferred stock had no expiration date. F1 · balance_after: Reflects a 1.2-for-1 forward stock split of the Issuer's common stock effected on October 18, 2018. F3 · ownership.nature: These shares are held directly by Longitude Venture Partners III, L.P. ("Longitude Venture III"). Longitude Capital Partners III, LLC ("Longitude Capital III") is the general partner of Longitude Venture III and may be deemed to have voting, investment and dispositive power with respect to these securities. Patrick G. Enright and Juliet Tammenoms Bakker, a member of the Issuer's board of directors, are the managing members of Longitude Capital III (each a "Manager" and collectively, the "Managers") and may each be deemed to share voting, investment and dispositive power with respect to these securities. Each of Longitude Capital III and the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| September 21, 2018 Filed Sep 25, 2018 16:43 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | PurchaseCommon Stock | 365,000 | $5.50 | $2,007,500.00 |
DisclosureSEC source: 0001209191-18-052151 · doc4.xml · nonDerivative · entry 1 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Longitude Venture Partners III, L.P. Disclosed balance after: 3,261,535 F1 · ownership.direct: These shares are held by Longitude Venture Partners III, L.P. ("Longitude Venture III"). This report is filed jointly by Longitude Capital Partners III, LLC ("Longitude Capital III"), Longitude Venture III, Patrick G. Enright ("Mr. Enright"), and Juliet Tammenoms Bakker ("Ms. Bakker"), all of whom share beneficial ownership of more than 10% of the capital stock of the Issuer. Longitude Capital III is the general partner of Longitude Venture III and may be deemed to share voting and investment power over the shares held by Longitude Venture III. Mr. Enright and Ms. Bakker are the managing members of Longitude Capital III and may be deemed to share voting and investment power over the shares held by Longitude Venture III. Each of Longitude Capital III, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein. F1 · ownership.nature: These shares are held by Longitude Venture Partners III, L.P. ("Longitude Venture III"). This report is filed jointly by Longitude Capital Partners III, LLC ("Longitude Capital III"), Longitude Venture III, Patrick G. Enright ("Mr. Enright"), and Juliet Tammenoms Bakker ("Ms. Bakker"), all of whom share beneficial ownership of more than 10% of the capital stock of the Issuer. Longitude Capital III is the general partner of Longitude Venture III and may be deemed to share voting and investment power over the shares held by Longitude Venture III. Mr. Enright and Ms. Bakker are the managing members of Longitude Capital III and may be deemed to share voting and investment power over the shares held by Longitude Venture III. Each of Longitude Capital III, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.